

SEMINAR

—セミナーのお知らせ—

Title

**Vasculotide, An Angiopoietin 1 Mimetic,
Protects Vascular Barrier Function In Acute Lung Injury**

Date

Wednesday, Sept. 19, 2018 1:30–2:30pm

Venue


**Biken Hall, 1st floor, Main Building, RIMD
微生物病研究所本館 1 F 微研ホール**

Speaker

Paul Van Slyke, Ph.D.
Chief Scientific Officer, Vasomune Therapeutics
Sunnybrook Research Institute

Vasomune
Therapeutics

<https://www.vasomune.com/>



Abstract

Tie2 is a receptor tyrosine kinase expressed primarily on endothelial cells throughout the body. Constitutive activation of this receptor, through engagement with its cognate ligand Angiopoietin 1, is critical to the maintenance of normal vascular barrier function. Dysregulation of the Tie2 pathway has been widely implicated in several critical care indications marked by vascular leak. As such, modulation of the Tie2 pathway has become a major target of interest for the pharmaceutical industry.

Vasomune Therapeutics, a private biotechnology company based in Toronto, Canada has recently entered into a Co-Development Agreement with AnGes, Inc. (Osaka) to develop Vasculotide, an Angiopoietin 1 mimetic, for the treatment of acute respiratory distress syndrome (ARDS). The concept for Vasculotide as well as preclinical proof-of-concept data derived from three different models of ARDS will be discussed.

Host

Prof. Nobuyuki Takakura (Dept. Signal Transduction)
高倉伸幸 教授 (情報伝達分野)

セミナーは英語で行われます。

大阪大学ファカルティ・ディベロップメント新任教員研修プログラムとして認定されています。

お問い合わせ：大阪大学微生物病研究所 企画広報推進室

Tel: 06-6879-8357 E-mail: biken-pr@biken.osaka-u.ac.jp

協力

Innovators Club
Osaka Univ.


RIMD
Research Institute for
Microbial Diseases
大阪大学微生物病研究所